Simcere Pharmaceutical Group Limited (HKG: 2096)

Market Cap	15.38B
Revenue (ttm)	6.81B
Net Income (ttm)	-1.18B
Shares Out	2.52B
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	14.52
Dividend	0.18 (2.88%)
Ex-Dividend Date	Jun 18, 2024

Volume	3,760,000
Open	5.91
Previous Close	6.10
Day's Range	5.86 - 6.06
52-Week Range	4.94 - 7.87
Beta	0.47
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. The company focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injecti...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 7,027
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2096

Financial Performance

In 2023, Simcere Pharmaceutical Group's revenue was 6.61 billion, an increase of 4.49% compared to the previous year's 6.32 billion. Earnings were 714.76 million, a decrease of -23.22%.

Financial numbers in CNY